NCT07094048View on ClinicalTrials.gov

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Multiple Myeloma RefractoryRelapsed Multiple Myeloma
Interventions
DRUG

Target trough IgG level of 8-10 g/L

Target trough IgG level of 8-10 g/L

DRUG

Target trough IgG level 4-6 g/L

Target trough IgG level of 4-6 g/L

DRUG

No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L

If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B

Trial Locations (1)

Unknown

Centre Intégré de Cancérologie, Québec

All Listed Sponsors
lead

CHU de Quebec-Universite Laval

OTHER